David Dowling | PI
Boston Children's Hospital

David Dowling, PI, Boston Children's Hospital

Dr. David Dowling is an immunologist and vaccinologist, Instructor in Pediatrics at Harvard Medical School and a faculty in the Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital. Dr. Dowling obtained a B.Sc. in Biotechnology (Hons) and Ph.D. in Immunology/Vaccinology/Parasitology at Dublin City University (in 2009), where his graduate work made groundbreaking progress in characterizing the immune-polarizing effects of parasite proteins and development of anti-helminth vaccines. David completed his postdoctoral research in the laboratory of Dr. Levy in the Division of Infectious Diseases, Boston Children’s Hospital, where he pioneered innovative use of primary human in vitro modeling, early life animal models in vivo, novel vaccine formulation strategies and multi-omics data integration to develop adjuvanted vaccines targeted to vulnerable populations. His work has resulted in multiple first-authored publications in journals such as the Vaccine, Journal of Clinical Investigation Insight, Journal of Immunology, ImmunoHorizons, Biomaterials, Molecular & Cellular Proteomics, the Journal of Allergy & Clinical Immunology and Trends in Immunology and numerous patent applications of novel intellectual property. David has played a key role in the conception and initiation of BCH’s Adjuvant Discovery (since 2014) and Development Programs (since 2018), NIH-funded contracts, aimed at discovering/developing novel small molecule adjuvants and formulating them to enhance immunization against pertussis and influenza in infants and the elderly, respectively. David is also a formal Fellow of the American Association of Immunologists AAI Public Policy Program, with a special focus on vaccinology, public and political awareness and NIH funding advocacy.

Appearances:



Pre-Congress Workshops - Monday 1st April @ 10:00

Vaccine Technology [M1]

Cutting-edge technologies shaping the future of vaccine development.  

10:00 Workshop Leader Opening RemarksDr Wolfgang Leitner, Chief, Innate Immunity Section, NIH

10:10 Innovating Vaccine Development: The Role of VaxArray in SolaVAX, a novel photochemical inactivation vaccine platformDr. Izabela Ragan DVM, Director of Research and Development, Solaris Vaccines

10:30 Revolutionizing mRNA Production: the paradigm-breaking Nfinty™ continuous RNA systemPatrick Thiaville, Chief Technologies Officer, Nucleic Acids, Exothera

10:45 A Novel Intranasal Adjuvant Show to be Safe and Immunogenic in HumansDr Chad Costley, CEO & President, Blue Willow Biologics

11:00 Use of adjuvants to enhance mucosal immunity after vaccinationDr Lisa Morici, Professor, Tulane University School of Medicine

11:15 MF59 Adjuvant Mimic: yeast derived squalene and alternative sourcesChase Kempinski, CEO, Enepret

11:30 Alternative uses for adjuvants & cross-over immunotherapy technologies Dr Jay Evans, Chief Scientific and Strategy Officer, Inimmune & Director of the Center for Translational Medicine at the University of Montana

11:45 New developments in vaccine adjuvant research: How has the pandemic changed the field?Dr Wolfgang Leitner, Chief, Innate Immunity Section, NIH

12:00 Utilizing AI in Adjuvant Discovery – Title TBCDr David Dowling, Scientist, Professor, Division of Infectious Diseases, Instructor in Pediatrics, Boston Children's Hospital & Harvard Medical School

12:15 Fine-Tuning Immunity, AI-Driven Adjuvant Discovery, Sustainable Formulations, and Novel Vaccine Delivery Strategies – Title TBCDr Aaron Esser-Kahn, Professor of Molecular Engineering, University of Chicago

12:30 Fireside Chat: Emerging discovery tools and technologiesModerator: Dr Jay Evans, Chief Scientific and Strategy Officer, Inimmune & Director of the Center for Translational Medicine, University of MontanaDr David Dowling, Scientist, Professor, Division of Infectious Diseases, Instructor in Pediatrics, Boston Children's Hospital & Harvard Medical SchoolDr Wolfgang Leitner, Chief, Innate Immunity Section, NIHDr Aaron Esser-Kahn, Professor of Molecular Engineering, University of Chicago

last published: 29/Mar/24 09:06 GMT

back to speakers